Stock Events

Stock Events

Calithera Biosciences 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1JanExpected
Q4 0
-2.3
-1.96
-1.63
-1.3
Expected EPS
-2.2973982724
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-20.1MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2CB.STU. It's not an investment recommendation.
NVIDIA
2
NVDA
Fluent
2
FLNT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap23.32B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including cancer treatments that directly compete with Calithera's oncology portfolio.
Exelixis
EXEL
Mkt Cap14.2B
Exelixis, Inc. is involved in the development and commercialization of cancer treatments, competing in the oncology space with drugs that may target similar pathways as Calithera's products.
Array Technologies
ARRY
Mkt Cap979.87M
Array BioPharma Inc. specializes in the development of drugs for the treatment of cancer, including targeted small molecule drugs designed to treat patients with specific mutations, competing with Calithera's approach to cancer therapy.
Agios Pharmaceuticals
AGIO
Mkt Cap2.45B
Agios Pharmaceuticals, Inc. focuses on cellular metabolism and rare genetic diseases, including cancer metabolism, which competes with Calithera's research into cancer cell metabolism.
Novartis
NVS
Mkt Cap293.94B
Novartis AG, through its extensive portfolio of oncology drugs, competes across a broad range of cancer types, potentially including those targeted by Calithera's treatments.
Puma Biotechnology
PBYI
Mkt Cap407.2M
Puma Biotechnology, Inc. focuses on the development and commercialization of a targeted therapy for breast cancer, competing in the oncology market where Calithera is also seeking to establish a presence.

About

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Show more...
CEO
Ms. Stephanie Wong CPA
Employees
8
Country
United States
ISIN
US13089P1012

Listings

STU
DE
2CB.STU
OTC Link
US
CALA

0 Comments

Share your thoughts

FAQ

What is Calithera Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Calithera Biosciences stocks are traded under the ticker 2CB.STU.
What is Calithera Biosciences revenue for the last year?▼
Calithera Biosciences revenue for the last year amounts to 0 EUR.
What is Calithera Biosciences net income for the last year?▼
2CB.STU net income for the last year is -20.1M EUR.
How many employees does Calithera Biosciences have?▼
As of July 22, 2026, the company has 8 employees.
In which sector is Calithera Biosciences located?▼
Calithera Biosciences operates in the Health & Wellness sector.
When did Calithera Biosciences complete a stock split?▼
The last stock split for Calithera Biosciences was on June 15, 2022 with a ratio of 1:20.
Where is Calithera Biosciences headquartered?▼
Calithera Biosciences is headquartered in South San Francisco, United States.